Key Highlights
- Freeflow Ventures raises $50M through $35M Fund Two and $15M Opportunity Fund.
- Firm now manages $90M in assets under management.
- New investment into Catena Bio, expanding focus to Berkeley.
- Freeflow Ventures has invested in over 30 companies since 2020.
- Notable investors include Nobel Laureates Frances Arnold, David Baltimore, and Bob Grubbs.
Source: Business Wire
Notable Quote
- “This new funding enables us to expand our model to Berkeley, an important addition to our operating model because it shares so many similarities to Caltech and JPL where amazing founders working on large-scale solutions to important problems continue to create high quality investment opportunities. These two communities align very nicely with our focused thesis on human and planetary health.” — David Fleck, Founder and Managing Partner at Freeflow Ventures
SoHC's Take
Freeflow Ventures’ latest $50M fundraise, doubling its assets under management, is a significant achievement in the challenging venture capital market. This expansion to Berkeley marks a strategic move, leveraging the deep tech innovation hubs at both Caltech and UC Berkeley. Their investment into Catena Bio highlights Freeflow’s commitment to groundbreaking science and technology solutions in healthcare, especially in the promising field of Antibody Drug Conjugate (ADC) technology for cancer treatment. With prominent figures like Nobel Laureates backing the firm, Freeflow Ventures is well-positioned to continue making impactful investments in human and planetary health.
